Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples